Based upon the highly restricted normal tissue expression of BCMA along with its frequent, high expression on malignant plasma cells, we undertook an effort to generate a CAR targeting BCMA for adoptive T cell therapy of multiple myeloma. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.